Peptidyl-Prolyl Isomerases: Functionality and Potential Therapeutic Targets in Cardiovascular Disease Publisher Pubmed



Rostam MA^{1, 2, 3} ; Piva TJ⁴ ; Rezaei HB^{1, 2, 5} ; Kamato D^{1, 2} ; Little PJ^{1, 2, 6} ; Zheng W⁷ ; Osman N^{1, 2, 6} Show Affiliations
Source: Clinical and Experimental Pharmacology and Physiology Published:2015

Abstract

Peptidyl-prolyl cis/trans isomerases (PPIases) are a conserved group of enzymes that catalyse the conversion between cis and trans conformations of proline imidic peptide bonds. These enzymes play critical roles in regulatory mechanisms of cellular function and pathophysiology of disease. There are three different classes of PPIases and increasing interest in the development of specific PPIase inhibitors. Cyclosporine A, FK506, rapamycin and juglone are known PPIase inhibitors. Herein, we review recent advances in elucidating the role and regulation of the PPIase family in vascular disease. We focus on peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (Pin1), an important member of the PPIase family that plays a role in cell cycle progression, gene expression, cell signalling and cell proliferation. In addition, Pin1 may be involved in atherosclerosis. The unique role of Pin1 as a molecular switch that impacts on multiple downstream pathways necessitates the evaluation of a highly specific Pin1 inhibitor to aid in potential therapeutic drug discovery. © 2014 The Authors. Clinical and Experimental Pharmacology and Physiology published by Wiley Publishing Asia Pty Ltd.